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Abstract: In 2017, a new two-step algorithm for the treatment of COPD was proposed. This
algorithm was based on the severity of symptoms and phenotypes or treatable traits, and
patient-specialised assessment targeting eosinophilic inflammation, chronic bronchitis, and
frequent infections is recommended after exacerbation occurs despite maximal bronchodila-
tion therapy. However, recent studies have revealed the clinical characteristics of patients
who should have second controllers added, such as ICS. We again realized that treatable
traits should be assessed and intervened for as early as possible. Moreover, the treatment
algorithm is necessary to be adapted to the situation of clinical practice, taking into account
the characteristics of the patients. The time to revise COPD treatment algorithm has come
and we propose a new 3-step parallel approach for initial COPD treatment. After the
diagnosis of COPD, the first assessment is to divide into two categories based on the usual
clinical characteristics for patients with COPD and the specific clinical characteristics for
each patient with concomitant disease. In the former, the assessment should be based on the
level of dyspnea and the frequency of exacerbations. After the assessment, mono- or dual
bronchodilator should be selected. In the latter, the assessment should be based on asthma
characteristics, chronic bronchitis, and chronic heart failure. After the assessment, patients
with asthmatic characteristics may consider treatment with ICS, while patients with chronic
bronchitis may consider treatment with roflumilast and/or macrolide, while patients with
chronic heart failure may consider treatment with selective β1-blocker. The 3-step parallel
approach is completed by adding an additional therapy for patients with concomitant disease
to essential therapy for patients with COPD. In addition, it is important to review the
response around 4 weeks after the initial therapy. This COPD management proposal might
be considered as an approach based on patients’ clinical characteristics and on personalized
therapy.
Keywords: parallel approach, treatable traits, ICS, personalized therapy
Introduction
In 2017, a new two-step algorithm for the treatment of chronic obstructive pul-
monary disease (COPD) was proposed.1 This treatment algorithm was based on the
severity of symptoms and history of exacerbations. It can be argued that these are
treatable traits. The algorithm underlies the importance to identify what are the
COPD exacerbation’s precipitating factors, in order to provide patients’ with
appropriate prevention therapy. In this algorithm, patient-specialised assessment
targeting eosinophilic inflammation, chronic bronchitis, and frequent infections is
recommended after exacerbation occurs despite maximal bronchodilation therapy.
However, even just one severe exacerbation appears to accelerate the decline in
lung function, inducing physical inactivity, poorer quality of life, and an increased
risk of death.2 Recent studies have revealed the clinical characteristics of patients
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who should be added second controllers such as inhaled
corticosteroids (ICS).3–6 Based on these evidence, we
again realized that treatable traits should be assessed and
intervened as early as possible. Moreover, the treatment
algorithm must be adapted to the situation of clinical
practice, taking into account the characteristics of the
patients. The time to revise COPD treatment algorithm
has come and we propose a new 3-step parallel approach
for initial COPD treatment.
State Of The Art
According to the latest 2019 update of the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) report,
pharmacological treatment was divided into two algo-
rithms, “initial treatment” and “follow-up treatment”.7
Initial pharmacological treatment has been recommended
by the ABCD grouping based on symptom burden and risk
of exacerbation after the initial diagnosis of COPD. In
initial pharmacological management, use of ICS is recom-
mended only for Group D patients with blood eosinophil
counts ≥ 300/μL or a history of asthma. If there is no
response to the initial treatment, GOLD 2019 report pro-
poses considering the predominant treatable trait to target
(dyspnea or exacerbations). The dyspnea algorithm path-
way recommends escalation using additional long-acting
bronchodilator (LABD) treatment for breathlessness. For
patients with breathlessness who are already treated with a
dual bronchodilator or dual bronchodilator and ICS com-
bination, it is recommended to switch molecules or inhaler
device and to investigate other possible causes of dyspnea
such as heart failure and pulmonary hypertension. The
exacerbation algorithm pathway recommends escalation
using additional LABD or ICS. If the above-mentioned
steps do not work, addition of roflumilast or macrolide was
recommended.
Algorithm
GOLD 2019 report and many other algorithms recommend
that the use of drugs other than LABDs should be after
exacerbation occurs. However, considering the burden of
exacerbations,8,9 it is very important to preemptive treat-
ment tailored to the treatable trait at the initial treatment.
There are various risk factors and triggers for
exacerbations,10 while risk factors and triggers can be
roughly divided into two categories. It is the usual clinical
characteristics for patients with COPD and the specific
clinical characteristics for patients with concomitant dis-
ease. The usual clinical characteristics for patients with
COPD are dyspnea, exacerbation, smoking, airflow limita-
tion and physical inactivity, while specific clinical charac-
teristics for patients with concomitant disease are chronic
bronchitis, cardiovascular disease, anxiety, depression and
other concomitant medical conditions.11 It is our firm belief
that the approach of considering the specific concomitant
disease in parallel with the usual clinical characteristics is
extremely important. We newly advocate a parallel
approach for the management of COPD (Figure 1).
In accordance with a concept of parallel approach for
the management of COPD, we propose a new 3-step
parallel approach for initial COPD treatment based on
the evidence of recent studies (Figure 2).
Once the diagnosis of COPD has been confirmed by
spirometry, the first assessment is to divide into two cate-
gories based on the usual clinical characteristics for
patients with COPD and the specific clinical characteris-
tics for each patient with concomitant disease.
In usual clinical characteristics for patients with COPD,
the assessment (Step 1: assessment) should be based on the
level of dyspnea (as measured by the modified Medical
Research Council dyspnea scale, mMRC) and the fre-
quency of exacerbations. After the assessment, patients
with a mMRC score of 0 or 1 or no more than one exacer-
bation during the previous year may start treatment with a
mono-bronchodilator [a long-acting muscarinic antagonist
(LAMA) or a long-acting β-agonist (LABA)] whereas
patients with either a mMRC score higher than 1 or with
more than one exacerbation in the previous year should start
with a dual bronchodilator (LABA/LAMA) (Step 2: drug
selection). For patients with persistent breathlessness on a
monotherapy of LABDs, there might be room to consider a
combination therapy of LABDs. Our proposal based on the
level of dyspnea and the frequency of exacerbations is
similar to the algorithm published by Miravitlles and
Anzueto in 2017.1 Additionally, for patients with COPD,
it goes without saying that smoking cessation, pulmonary
rehabilitation (or regular exercise) and vaccination are
important as a treatment other than bronchodilator, and
they should be included under general recommendations
to all patients.7
In specific clinical characteristics for patients with con-
comitant disease, the assessment (Step 1: assessment)
should be based on the asthma characteristics, chronic
bronchitis,12 and chronic heart failure.13 Most importantly,
our approach differs from many other algorithms in that
the use of ICS has priority for the patients with asthma
characteristics. There is now more evidence that patients
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with COPD and characteristics of asthma [asthma-COPD
overlap (ACO)] are recognized in several national and
international guidelines.14–16 Because the definitive defini-
tion and diagnostic criteria have not been established, the
prevalence of ACO among patients previously diagnosed
as COPD has varied widely in studies: from 15% to
55%.14 To manage COPD patients with asthma character-
istics effectively, it is important to make the diagnosis.17 It
is inaccurate to distinguish based on clinical characteristics
because no significant difference was observed in baseline
characteristics between patients with ACO and non-
ACO.18 Therefore, ACO patients without history of
asthma are easily overlooked. There is a COPD subgroup
characterized by asthma-like gene expression signatures of
type 2 inflammation associated with airway eosinophilia
and ICS responsiveness.19 In clinical practice, the desig-
nation of the type 2 signature is commonly used in the
presence of atopy and/or eosinophilic inflammation, iden-
tified on the basis of blood eosinophilia (≥ 300/μL) and
high level of fraction of exhaled nitric oxide (FeNO) (≥ 35
ppb). Although FeNO has variability in patients with
COPD,20 these persistently elevated type 2 biomarkers
may reflect eosinophilic airway inflammation and predict
ICS responsiveness in patients with COPD.3–6 After the
assessment, patients with asthmatic characteristics may
consider treatment with ICS (Step 2: drug selection).
From the viewpoint of the effectiveness and the risk of
side effects such as pneumonia, osteoporosis and myco-
bacterial infection, there is a need to identify which
patients will benefit from ICS.
Patients with chronic bronchitis may consider treatment
with roflumilast and/or macrolide (Step 2: drug selection).
Although gastrointestinal adverse effects and weight loss
were common, pooled analysis of recently completed two
phase IV clinical studies confirmed the benefit of the phos-
phodiesterase (PDE) 4 inhibitor roflumilast in preventing
exacerbations in patients with prior hospitalization for
exacerbation and higher exacerbation frequency.21 The
mechanisms for the helpful therapeutic effects of macrolide
can go beyond their direct anti-infective effect because
latest data presented that they exert multiple effects on the
structure and composition of the lower airway microbiota
with increased production of bacterial metabolites with anti-
inflammatory properties.22,23 Mucolytic therapy such as
N-acetylcysteine, ambroxol or carbocisteine can also be
considered for patients with chronic bronchitis. The ERS/
ATS task force on the management of COPD exacerbations
has reported the beneficial effect of the high-dose mucolytic
Figure 1 A concept of parallel approach for the management of chronic obstructive pulmonary disease (COPD).
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agent in patients with frequent exacerbation despite optimal
inhaled therapy.24
Patients with chronic heart failure may consider treatment
with selective β1-blocker (Step 2: drug selection). The pre-
valence of heart failure patients combined with COPD is one-
third.25 β-Blockers were thought to be potentially unsafe to
COPD patients. However, a reduction in COPD-related mor-
tality of 31% with usage of new selective β1-blocker was
pointed out in a systematic review and meta-analysis of retro-
spective cohort studies.26 Despite increasing evidence that
selective β1-blocker is safe and beneficial in patients with
COPD, they are often underused in this group worldwide.
The 3-step parallel approach is completed by adding
the additional therapy for patients with concomitant dis-
ease to essential therapy for patients with COPD (Step 3:
initial therapy). In addition, it is important to review the
response around 4 weeks after the initial therapy. The
evaluation factors are inhaler technique, adherence, symp-
toms, exacerbations, side effects, patient satisfaction, lung
function and eosinophilic inflammation.
We now recognize that COPD patients also have other
concomitant conditions which include anxiety/depression,
skeletal muscle dysfunction, osteoporosis, gastroesopha-
geal reflux (GERD), bronchiectasis, metabolic syndrome,
and lung cancer. COPD patients had a higher prevalence of
anxiety/depression, and anxiety/depression are associated
with poorer quality of life and survival.27 In contrast, there
remain unanswered questions about adequate treatment
strategies of comorbid anxiety/depression in patients with
COPD. Skeletal muscle dysfunction affects both ventila-
tory and nonventilatory muscle groups, leading to poor
quality of life and increasing mortality.28 Muscle recovery
actions combined with pulmonary rehabilitation and
optimized nutrition contribute to a better prognosis.
Osteoporosis in COPD are often underdiagnosed and
undertreated.29 Although there is no evidence that osteo-
porosis treatment improves the prognosis of COPD
patients, it seems reasonable to treat osteoporosis accord-
ing to usual guidelines. GERD is known to be a risk factor
for frequent exacerbation.11 Although there is not enough
Figure 2 A new 3-step parallel approach for initial chronic obstructive pulmonary disease (COPD) treatment.
Abbreviations: mMRC, modified Medical Research Council dyspnoea scale; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled
corticosteroids; FeNO, fraction of exhaled nitric oxide.
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evidence in pharmacological treatment, proton pump inhi-
bitors may be effective for COPD patients with GERD.30
Bronchiectasis coexisting with COPD is often identified
with an increasing use of computed tomography (CT) in
the assessment of COPD patients.31 It is associated with
longer exacerbations and increased mortality.32,33 COPD
patients with bronchiectasis might be a potential popula-
tion to benefit from macrolide and/or mucolytic therapy.
Moreover, since there is significant evidence that the use
of ICS increases the risk of mycobacterium infection in
patients with COPD,34 we should consider bronchiectasis
in the initial assessment. Lung cancer is common in COPD
patients and one of the main cause of death. Smoking
cessation is very important not only for the treatment of
COPD but also for the prevention of lung cancer.
It is fully known that the proposed algorithm will need
to be validated, particularly in the real world. Moreover,
there are some limitations to use this algorithm. Medical
resources vary greatly from country to country. At the
present time, roflumilast is not approved in many Asian
countries. In some areas, there is difficult access to some
diagnosis tools, such as CT, echocardiography, and FeNO.
Low utilization of these diagnostic techniques is a signifi-
cant barrier to adequate disease management.
Conclusion
This perspective article proposes to identify treatable clin-
ical features early and to treat usual and specific clinical
characteristics in parallel. The management of COPD
patients should be a teamwork among primary care provi-
ders, pulmonary specialists, and other physicians. This
new 3-step parallel approach might be a restructuring of
the existing approach of treatment of COPD and consid-
ered as an approach based on patients’ clinical character-
istics and on personalized therapy.
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